[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018003175A - 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. - Google Patents

177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.

Info

Publication number
MX2018003175A
MX2018003175A MX2018003175A MX2018003175A MX2018003175A MX 2018003175 A MX2018003175 A MX 2018003175A MX 2018003175 A MX2018003175 A MX 2018003175A MX 2018003175 A MX2018003175 A MX 2018003175A MX 2018003175 A MX2018003175 A MX 2018003175A
Authority
MX
Mexico
Prior art keywords
ipsma
hynic
dota
radiopharmaceutical
new
Prior art date
Application number
MX2018003175A
Other languages
English (en)
Inventor
Ferro Flores Guillermina
Elí Ocampo García Blanca
Leticia Santos Cuevas Clara
Alejandra Luna Gutiérrez Myrna
Patricia Azorín Vega Erika
Patricia Jiménez Mancilla Nallely
Hernández Jiménez Tania
De María Ramírez De La Cruz Flor
Original Assignee
Instituto Nac De Investigaciones Nucleares
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Nac De Investigaciones Nucleares filed Critical Instituto Nac De Investigaciones Nucleares
Priority to MX2018003175A priority Critical patent/MX2018003175A/es
Priority to CA3093819A priority patent/CA3093819A1/en
Priority to ES19768668T priority patent/ES2960729T3/es
Priority to CN201980029761.0A priority patent/CN112074526B/zh
Priority to US16/980,252 priority patent/US12128114B2/en
Priority to PCT/MX2019/000025 priority patent/WO2019177449A1/es
Priority to MA052029A priority patent/MA52029A/fr
Priority to EA202092176A priority patent/EA202092176A1/ru
Priority to EP19768668.6A priority patent/EP3766893B1/en
Priority to BR112020018155-2A priority patent/BR112020018155A2/pt
Publication of MX2018003175A publication Critical patent/MX2018003175A/es
Priority to ZA2020/05600A priority patent/ZA202005600B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención se refiere a un nuevo radiofármaco terapéutico de lutecio-177 como inhibidor del antígeno prostático específico de membrana (iPSMA), donde el ácido 1,4,7,10-tetraazaciclododecano-N, N´,N´´,N´´´´-tetraacético (DOTA) unido a la molécula hidrazinonicotinamida (HYNIC) de naturaleza heterocíclica, genera una estructura química rígida que minimiza el número de confórmeros y enlaces de hidrógeno intramoleculares, produciendo una orientación espacial favorable del sitio activo (Lys(Nal)-NH-CO-NH-Glu) en la molécula para el reconocimiento biológico por la proteína PSMA. El nuevo radiofármaco de 177Lu-DOTA-HYNIC-iPSMA se acumula, con alta afinidad in vivo, en tumores que sobre-expresan a la proteína PSMA, actuando como un agente radioterapéutico. El objeto de esta invención es proporcionar un nuevo radiofármaco específico (radiofármaco de blancos moleculares) para el tratamiento de tumores con sobre-expresión de PSMA.
MX2018003175A 2018-03-14 2018-03-14 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. MX2018003175A (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2018003175A MX2018003175A (es) 2018-03-14 2018-03-14 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.
PCT/MX2019/000025 WO2019177449A1 (es) 2018-03-14 2019-03-07 177lu-dota-hynic-ipsma como un radiofármaco terapéutico dirigido al antígeno prostático específico de membrana
ES19768668T ES2960729T3 (es) 2018-03-14 2019-03-07 177 Lu-dota-hynic-ipsma como un radiofármaco terapéutico dirigido al antígeno prostático específico de membrana
CN201980029761.0A CN112074526B (zh) 2018-03-14 2019-03-07 作为治疗性放射性药物的177Lu-DOTA-HYNIC-iPSMA
US16/980,252 US12128114B2 (en) 2018-03-14 2019-03-07 177Lu-DOTA-HYNIC-iPSMA as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
CA3093819A CA3093819A1 (en) 2018-03-14 2019-03-07 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
MA052029A MA52029A (fr) 2018-03-14 2019-03-07 177lu-dota-hynic-ipsma utilisé en tant que produit radiopharmaceutique thérapeutique dirigé contre l'antigène prostatique spécifique de membrane
EA202092176A EA202092176A1 (ru) 2018-03-14 2019-03-07 177Lu-DOTA-HYNIC-iPSMA В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО РАДИОФАРМАЦЕВТИЧЕСКОГО СРЕДСТВА, НАЦЕЛЕННОГО НА ПРОСТАТИЧЕСКИЙ СПЕЦИФИЧЕСКИЙ МЕМБРАННЫЙ АНТИГЕН
EP19768668.6A EP3766893B1 (en) 2018-03-14 2019-03-07 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
BR112020018155-2A BR112020018155A2 (pt) 2018-03-14 2019-03-07 177lu-dota-hynic-ipsma como um radiofármaco terapêutico dirigido ao antígeno prostático específico de membrana
ZA2020/05600A ZA202005600B (en) 2018-03-14 2020-09-09 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2018003175A MX2018003175A (es) 2018-03-14 2018-03-14 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.

Publications (1)

Publication Number Publication Date
MX2018003175A true MX2018003175A (es) 2019-09-16

Family

ID=67907935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003175A MX2018003175A (es) 2018-03-14 2018-03-14 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.

Country Status (11)

Country Link
US (1) US12128114B2 (es)
EP (1) EP3766893B1 (es)
CN (1) CN112074526B (es)
BR (1) BR112020018155A2 (es)
CA (1) CA3093819A1 (es)
EA (1) EA202092176A1 (es)
ES (1) ES2960729T3 (es)
MA (1) MA52029A (es)
MX (1) MX2018003175A (es)
WO (1) WO2019177449A1 (es)
ZA (1) ZA202005600B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3176404A1 (en) * 2020-04-24 2021-10-28 Ebrahim S. Delpassand Composition, kit and method for diagnosis and treatment of prostate cancer
EP4244216A1 (en) * 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
CN112851637B (zh) * 2021-01-22 2022-11-18 北京瑞达福明科技有限公司 一种psma抑制剂、化合物及其制备方法与用途
JP2024512283A (ja) * 2021-02-26 2024-03-19 テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド グルタメート－尿素－リジン由来（ｇｕｌ由来）前立腺特異的膜抗原（ｐｓｍａ）標的化コンジュゲートの固相合成並びに治療剤及び／又は診断剤のための前駆体としてのそれらの使用
WO2022226326A1 (en) * 2021-04-23 2022-10-27 Wisconsin Alumni Research Foundation Psma-targeting ligands with optimal properties for imaging and therapy
MX2021005088A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Nanoparticulas radioluminiscentes de sesquioxido de lutecio-177 funcionalizadas con peptidos para imagen optica.
CN115745903B (zh) * 2021-09-03 2024-07-23 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN115260155B (zh) * 2022-08-08 2023-11-10 北京师范大学 一种含三唑环和肼基尼古酰胺基的谷氨酸-脲衍生物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014721A1 (en) * 2005-06-30 2007-01-18 Harris Thomas D Hydrazide conjugates as imaging agents
MX336322B (es) 2010-04-08 2016-01-12 Inst Nac De Investigaciones Nucleares 99mtc-edda/hynic-ggc-aunp-manosa como un nuevo radiofarmaco para la deteccion del ganglio centinela en cancer de mama.
HRP20240398T1 (hr) 2013-10-18 2024-06-07 Novartis Ag Označeni inhibitori prostata specifičnog membranskog antigena (psma), njihova upotreba kao sredstava za snimanje i farmaceutska sredstva za liječenje raka prostate
WO2016043793A1 (en) * 2014-09-15 2016-03-24 Shelterlogic Corp. Shelter structure and methods of constructing same
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
MX2016008466A (es) * 2016-06-24 2017-12-25 Instituto Nac De Investigaciones Nucleares 99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana.
JP2024512283A (ja) * 2021-02-26 2024-03-19 テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド グルタメート－尿素－リジン由来（ｇｕｌ由来）前立腺特異的膜抗原（ｐｓｍａ）標的化コンジュゲートの固相合成並びに治療剤及び／又は診断剤のための前駆体としてのそれらの使用

Also Published As

Publication number Publication date
EP3766893B1 (en) 2023-07-19
CN112074526B (zh) 2024-02-20
EP3766893C0 (en) 2023-07-19
EA202092176A1 (ru) 2021-02-24
US20210015949A1 (en) 2021-01-21
CA3093819A1 (en) 2019-09-19
EP3766893A1 (en) 2021-01-20
MA52029A (fr) 2021-01-20
ZA202005600B (en) 2021-08-25
WO2019177449A1 (es) 2019-09-19
US12128114B2 (en) 2024-10-29
EP3766893A4 (en) 2022-02-16
BR112020018155A2 (pt) 2021-02-02
CN112074526A (zh) 2020-12-11
ES2960729T3 (es) 2024-03-06

Similar Documents

Publication Publication Date Title
MX2018003175A (es) 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.
MX2017014083A (es) Polipeptido de fusion anti-cancer.
CY1113394T1 (el) Αντισωματα toy pan-kir2dl νκ υποδοχεα και η χρηση τους στη διαγνωση και τη θεραπεια
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
HUP0401534A2 (hu) Módosított humán IX. faktor
CY1118222T1 (el) Συνθεσεις λυασης φαινυλαλανινης αμμωνιας προκαρυωτικων και μεθοδοι αγωγης καρκινου χρησιμοποιωντας συνθεσεις εξ' αυτης
DE602004011770D1 (de) Fusionsproteine
EA200501798A1 (ru) Новые пептиды, которые связываются с рецептором к эритропоэтину
NZ626620A (en) Enhancement of transport of therapeutic molecules across the blood brain barrier
MY156286A (en) Human il-23 antigen binding proteins
GEP20125385B (en) Antibodies directed against amyloid-beta peptide and methods using same
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
DK1549353T3 (da) Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
MX2023002330A (es) Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos.
WO2020103961A3 (zh) 一种脑部肿瘤靶向肽及其应用
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
MX2019002664A (es) Proteina de union a antigeno contra her3.
MX2023006869A (es) Proteinas de union condicionalmente biespecificas.
Abouzayed et al. Preclinical evaluation of the GRPR-targeting antagonist RM26 conjugated to the albumin-binding domain for GRPR-targeting therapy of cancer
SI2089433T1 (sl) Terapevtsko ciljan katepsin s
IL212653A0 (en) Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
ATE514718T1 (de) Peptabody für krebsbehandlung
ATE480552T1 (de) Stq-peptide